PLANEGG-MARTINSRIED, Germany--(BUSINESS WIRE)--4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development company, today announced that the European Patent Office has granted patent EP1392642, which covers its lead auto-immune compound 4SC-101. This small molecule is a DHODH and IL-17 inhibitor which is currently in Phase II trials in rheumatoid arthritis and inflammatory bowel disease.
